|
|
||||||||
| ABSTRACT |
|
|
|---|
| INTRODUCTION |
|
|
|---|
We have previously identified a 63-kD antigen in different extracts of Schistosoma mansoni cercariae, adult worms, and eggs and in the urine of S. mansoni-infected individuals by an IgG2a-specific monoclonal antibody (MAb).6 In the present study, we have evaluated both the placental and oral delivery of the 63-kD S. mansoni antigen from infected mothers to their newborns.
| MATERIALS AND METHODS |
|
|
|---|
Detection of total IgM in cord blood serum samples.
After optimization of reaction conditions, polystyrene, flat-bottom, microtiter plates were coated with 50 µL/well of cord blood serum diluted 1:100 in carbonate buffer, pH 9.6. After blocking with 0.3% nonfat milk, 50 µL/well of anti-human IgM alkaline phosphatase conjugate (Sigma, St. Louis, MO) diluted 1:750 in phosphate-buffered saline (PBS), pH 7.2, containing 0.05% Tween 20 (PBS-T20) was added and the plates were incubated for one hour at 37°C. Substrate (1 mg/mL of p-nitropheny1 phosphate; Sigma) was then added, and the absorbance was read at 405 nm using a
960 microplate autoreader (Axiom, Burstadt, Germany). The cut-off optical density (OD) value for ELISA positivity (0.055) was the mean OD plus three standard deviation values for 10 cord blood sera.
Samples collected during the breast-feeding period and after parturition. Twenty-five infants born to S. mansoni-infected mothers and five infants born to uninfected mothers served as negative controls and were followed during the breast-feeding period (1824 months) and for four weeks after parturition. Urine, serum, and breast milk samples were collected from their mothers. Only urine samples were collected from the 30 newborns during the breast-feeding period. After parturition of the 30 newborns, a urine sample was collected weekly from each child for one month. During these periods, all infants were not exposed to sources of Schistosoma infection. Complete clinical examinations were performed for all infants, and none showed Schistosoma eggs in their stool during the study.
Schistosoma mansoni soluble egg antigen. Soluble egg antigen (SEA) was prepared according to the method of da Silva and Ferri.9 The protein content was determined using the Lowry method.10 The antigenic extract was stored at -70°C until use.
Sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) was carried out in 0.75 mm-thick, 16% vertical slab gels according to the method of Laemmli.11 Serial concentrations of the tested samples (SEA, maternal blood serum, cord blood serum, urine, and breast milk) were mixed with the sample buffer (0.125 M Tris base, 4% SDS, 20% glycerol, 10% ß-mercaptoethanol, and 0.1% bromophenol blue as a tracking dye) and immediately boiled for three minutes. A mixture of reference proteins (Promega, Madison, WI) was run in parallel. Gels were then stained with Coomassie blue or silver.
Gel electroelution. The band of interest (63 kD) was cut from preparative polyacrylamide gels and electroeluted from the gels in a dialysis bag (Sigma) as described by Attallah and others.6 The protein content of the purified antigen was then determined10 and the antigen was stored at -70°C until use.
Western blotting. Resolved samples separated by SDS-PAGE were electro-transferred12 onto nitrocellulose membranes (0.45 µm pore size). Blotting was carried out with at a constant voltage of 60 volts for two hours. The immunoassay was then performed using an IgG2a MAb (C5C4), followed by incubation for two hours with goat anti-mouse IgG alkaline phosphatase conjugate (Sigma).6 The nitrocellulose membrane was then soaked in premixed alkaline phosphatase substrate (5-bromo-4-chloro-3-indolyl phosphate [BCIP], nitro blue tetrazolium [NBT], and 0.1 M Tris buffer, pH 9.6; ABC Diagnostics, New Damietta, Egypt). The color was observed within 10 minutes and the reaction was stopped by the addition of distilled water.
Measurement of human schistosome-specific antibody response using an ELISA.
The specific IgG and IgM antibodies against the purified 63-kD Schistosoma antigen and SEA were evaluated in maternal blood serum and cord blood serum using the indirect ELISA described by Attallah and others.7 Briefly, flat-bottom, polystyrene, microtiter plates (Corning Life Sciences, Acton, MA) were coated with 2.5 µg/well of 63-kD antigen or 1.25 µg/well of SEA. After blocking with 0.3% nonfat milk, maternal and cord serum samples diluted 1:200 in PBS-T20 were added (50 µL/well), and the plates were incubated for two hours at 37°C. The plates were then washed five times with PBS-T20, anti-human IgG (or IgM) alkaline phosphatase conjugate (The Binding Site, Birmingham, United Kingdom) diluted 1:500 was added and incubated for one hour at 37°C. The plates were then washed again and substrate (p-nitrophenyl phosphate in 0.1M glycine buffer, pH 10.4) was added and the plates were incubated for 20 minutes at 37°C. The ODs were read at 405 nm using a
960 microplate autoreader. The maternal and cord blood sera of 10 uninfected women were used to set the cutoff limit of the ELISA. The cut-off OD for IgG ELISA positivity to 63-kD antigen was 0.235 (the mean OD plus three standard deviation values for samples from uninfected women). The cut-off OD was 0.351 for IgG ELISA positivity to SEA and 0.158 for IgM-ELISA positivity to SEA.
Dot-ELISA. A dot-ELISA,6,7 a sensitive and specific assay for qualitative detection of Schistosoma antigens in urine, was adapted to detect the reactivity of the 63-kD Schistosoma circulating antigen in blood serum and cord blood serum. All the assay steps were carried out on the surface of nitrocellulose membranes fixed in plastic device. Two hundred microliters of serum sample diluted 1:10 in PBS, pH 7.2, were added per dot. Blocking of the non-specific binding sites on the nitrocellulose membrane was done with 5% bovine serum albumin (Sigma) in PBS. The C5C4 mAb was then added at a dilution of 1:300 in PBS. After the samples were washed three times with PBS, anti-mouse IgG alkaline phosphatase conjugate (Sigma) at a dilution of 1:500 in PBS was added. The color was developed after addition of alkaline phosphatase premixed BCIP/NBT substrate system (ABC Diagnostics) for two minutes. The reaction was then stopped with distilled water and the result was recorded. The purple color produced in the dot-ELISA for a positive antigen test result varied in intensity from weak (1+, 2+) to strong (3+, 4+) according to the level of antigen in the serum.
Statistical analysis. All parameters were transferred to an IBM (Yorktown Heights, NY) PC/AT compatible computer for analysis using statistical analysis program package Instate Software for Science, version 2.3 (Graphpad Software, Inc., San Diego, CA). Non-parametric statistical methods were applied to evaluate the results. Concordance was assessed by Spearmans rank correlation. P values are two-tailed and the significance of difference follow the following arbitrary scheme: P > 0.05 (not significant), P < 0.05 (significant), P < 0.01 (very significant), and P < 0.001 (extremely significant).
| RESULTS |
|
|
|---|
= 0.72, P < 0.001). No false-positive results were found among 25 uninfected pregnant women used as controls.
|
= 0.09, P > 0.05). In addition, no significant correlation was shown between the levels of specific IgG antibodies to the 63-kD antigen and egg counts of the infected women (n = 47; Spearmans
= 0.06, P > 0.05).
Detection of Schistosoma antigen and specific antibody in cord blood.
Schistosoma antigen was detected by the dot-ELISA in 149 (86%) of 174 cord blood sera of S. mansoni-infected mothers. No false positive results were found in cord sera of 25 uninfected controls. The C5C4 mAb also identified by Western blotting a polypeptide band with a molecular mass of 63-kD in cord blood sera collected from 75 randomly selected S. mansoni-infected pregnant women. No reactive bands were shown in cord blood sera of 25 uninfected pregnant women (Figure 1
). Specific IgG antibodies to SEA and the 63-kD antigen were detected in 81% and 80%, respectively, of cord blood sera from 174 infected pregnant women. These antibodies were not detected in cord blood sera of 25 uninfected controls.
Detection of Schistosoma antigen in breast milk and in urine of young children during the breast-feeding period.
Western blotting identified the 63-kD Schistosoma antigen in urine samples of all 25 infants, as well as in breast milk and serum samples collected from their infected mothers during the breast-feeding period (1824 months) (Figure 2
). No false-positive results were found among five negative control mothers and their infants during this period. The dot-ELISA detected the 63-kD Schistosoma antigen in urine samples of all 25 infants born to S. mansoni-infected mothers, as well as in sera collected from their infected mothers during that period.
|
|
| DISCUSSION |
|
|
|---|
Few reports have appeared in the literature suggesting that maternal schistosome antigens are transferred through the placenta.1517 Carlier and others,15 using polyclonal antibodies, detected a circulating S. mansoni antigen in sera from umbilical cords of newborns of S. mansoni-infected mothers. Hassan and others17 detected Schistosoma carbohydrate antigens by a capture ELISA in 66% of the urine samples from newborns of 45 S. mansoni-infected mothers. We have identified and characterized a 63-kD Schistosoma antigen in adult worms, eggs, and cercariae antigenic extracts of S. mansoni and S. haematobium using the C5C4 mAb.6 In the present work, we at first investigated the possibility of placental and oral delivery of a 63-kD maternal Schistosoma antigen. The placental delivery of intact 63-kD antigen was then evaluated. The 63-kD Schistosoma antigen was identified in umbilical cord serum and breast milk samples, as well as in serum and urine samples from S. mansoni-infected women. In addition, the natural immunogenicity of the 63-kD antigen was identified by the detection of the specific IgG antibodies to this antigen in 91% of the sera of infected pregnant women. However, no correlation was shown between the levels of specific IgG antibodies to the 63-kD antigen and the serum antigen levels of infected women. Although the relationship between the level of 63-kD antigen in sera of the infected women and egg counts was significant, the levels of specific IgG antibodies to the 63-kD antigen were not significantly correlated with the egg counts of 47 infected women. However, a large number of samples are needed to make any final conclusions. The 63-kD antigen was detected in 86% of a large number of cord blood serum samples from infected women. Specific IgG antibodies to the 63-kD antigen were also detected in 80% of cord blood sera from infected pregnant women. The detection of the this Schistosoma antigen in sera from infected mothers and their cord blood sera demonstrates the transplacental transfer of the intact 63-kD antigen.
In the second part of the present study, 25 healthy infants were evaluated for the influence of their feeding pattern on the mother-to-child transmission of S. mansoni antigens. The 63-kD Schistosoma antigen was detected in the urine of the 25 newborns breast-fed by infected mothers that were followed two years after delivery. These data suggest that S. mansoni antigen can be transmitted in the colostrum/milk of infected mothers to their infants. Hassan and others17 hypothesized that a decrease of antigenemia (0% at six months of age) was due to the absence of a parasitic source of antigens in the infants and the elimination of schistosome antigens through the liver and kidneys within three months. In our study, the antigenemia persisted for 1824 months, indicating the presence of another source of schistosome antigen delivery, i.e., breast milk. The 63-kD Schistosoma antigen was identified in the breast milk of the infected mothers. We confirmed the oral transfer of the intact Schistosoma antigen, in which the target antigen was not detected in the urine of some infants up to 21 days after parturition, then disappeared at 28 days.
Rueff-Juy and others18 strongly suggested that oral transfer of maternal immunoglobulins is more efficient at inducing and maintaining tolerance than placental transfer and that regulatory T cells with suppressor activity are involved in this process. The oral and placental transfer of maternal Schistosoma antigens might also maintain tolerance after future vaccination. Ichino and others19 examined the influence of a number of factors on the development of neonatal tolerance, including the nature, concentration, and mode of antigen presentation to the immune system, and the age of the host. They found that the induction of neonatal tolerance was critically dependent on the age of the recipient, the timing of vaccine administration, and the dose of vaccine, but was not restricted by the major histocompatibility complex. They also suggested that CD8+T cells were required for induction of tolerance.19 However, other mechanisms might account for the development of tolerance, and some of these involve cells that are not of the CD8+ phenotype.20
Thus, we have identified and confirmed the oral and placental transfer of an intact S. mansoni antigen. Further studies to fully establish the mechanisms involved in the influence of placental versus oral delivery of Schistosoma antigens on immunoregulation are needed.
Received August 7, 2002. Accepted for publication January 9, 2003.
Acknowledgment: We thank Dr. M. Zazouk for his kind help during the collection of maternal and cord blood samples.
Authors addresses: Abdelfattah M. Attallah (amattallah{at}hotmail.com), Gamal E. Ghanem, and Hisham Ismail Osman (himosman{at}hotmail.com), Biotechnology Research Center, 23 July Street, Industrial Zone, PO Box 14, New Damietta City, Egypt, Telephone: 20-57-402-889, 403-889, 404-889, Fax: 20-57-401-889. Ahmed M. El-Waseef, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt.
| REFERENCES |
|
|
|---|
This article has been cited by other articles:
![]() |
S. Metenou, A. L. Suguitan Jr., C. Long, R. G. F. Leke, and D. W. Taylor Fetal Immune Responses to Plasmodium falciparum Antigens in a Malaria-Endemic Region of Cameroon J. Immunol., March 1, 2007; 178(5): 2770 - 2777. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |